News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
373,040 Results
Type
Article (25653)
Company Profile (66)
Press Release (347321)
Section
Business (104183)
Career Advice (442)
Deals (16878)
Drug Delivery (42)
Drug Development (47486)
Employer Resources (47)
FDA (12222)
Job Trends (8415)
News (185706)
Policy (19385)
Tag
Academia (1732)
Allergies (45)
Alliances (26518)
Alzheimer's disease (711)
Approvals (12175)
Artificial intelligence (70)
Bankruptcy (136)
Best Places to Work (6788)
Breast cancer (78)
Cancer (577)
Cardiovascular disease (60)
Career advice (403)
Cell therapy (100)
Clinical research (39127)
Collaboration (183)
COVID-19 (1445)
Data (580)
Diabetes (81)
Diagnostics (3331)
Drug pricing (45)
Earnings (35645)
Employer resources (45)
Events (50128)
Executive appointments (158)
FDA (12563)
Funding (152)
Gene therapy (60)
GLP-1 (304)
Government (2988)
Healthcare (12115)
Infectious disease (1486)
Inflammatory bowel disease (65)
IPO (6977)
Job creations (1835)
Job search strategy (375)
Layoffs (149)
Legal (3610)
Liver cancer (47)
Lung cancer (118)
Manufacturing (54)
Medical device (12666)
Medtech (12669)
Mergers & acquisitions (9949)
Metabolic disorders (219)
Neuroscience (858)
NextGen Class of 2024 (3923)
Non-profit (2810)
Northern California (624)
Obesity (130)
Opinion (60)
Patents (50)
People (33995)
Phase I (11164)
Phase II (16942)
Phase III (13935)
Pipeline (120)
Postmarket research (1665)
Preclinical (3489)
Radiopharmaceuticals (156)
Rare diseases (86)
Real estate (2838)
Regulatory (13605)
Research institute (1596)
Resumes & cover letters (48)
Southern California (562)
Startups (2115)
United States (6396)
Vaccines (276)
Weight loss (101)
Date
Last 7 days (435)
Last 30 days (1504)
Last 365 days (20064)
2024 (16964)
2023 (22745)
2022 (30700)
2021 (33009)
2020 (32218)
2019 (28426)
2018 (21817)
2017 (18911)
2016 (18111)
2015 (21194)
2014 (16023)
2013 (13241)
2012 (14349)
2011 (14624)
2010 (13184)
Location
Africa (353)
Arizona (85)
Asia (23978)
Australia (3788)
California (1364)
Canada (695)
China (133)
Colorado (71)
Connecticut (71)
Delaware (43)
Europe (46782)
Florida (254)
Georgia (59)
Illinois (204)
Indiana (120)
Kansas (67)
Maryland (380)
Massachusetts (1005)
Michigan (59)
Minnesota (163)
New Hampshire (50)
New Jersey (506)
New York (455)
North Carolina (376)
Northern California (624)
Ohio (75)
Pennsylvania (454)
South America (518)
Southern California (562)
Texas (231)
Washington State (121)
373,040 Results for "hansa medical".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
Hansa Biopharma Completes Randomization in Pivotal Phase 3 US ConfIdeS Trial
Hansa Biopharma AB, (“Hansa” or the “Company”) (NASDAQ Stockholm: HNSA), today announced recruitment and randomization in its US ConfIdeS trial is complete.
May 31, 2024
·
8 min read
Hansa Biopharma to present data at 2024 American Transplant Congress annual meeting
. Hansa Biopharma, “Hansa”, announced data featuring imlifidase will be presented at the American Transplant Congress, the joint annual meeting of the American Society of Transplant Surgeons and the American Society of Transplantation.
May 21, 2024
·
7 min read
Business
Hansa Biopharma interim report January-March 2024
Hansa Biopharma, the pioneer in immunomodulatory enzyme technology for rare IgG mediated diseases, announced its business update and year-end report for January to March 2024.
April 18, 2024
·
8 min read
Hansa Biopharma publishes 2023 Annual and Sustainability Reports
Hansa Biopharma AB announced the publication of its 2023 Annual and Sustainability Reports.
March 21, 2024
·
4 min read
Hansa Biopharma: increase in number of shares and votes
Hansa Biopharma AB, announced that the company’s registered share capital and number of shares and votes have increased through the issue of 10,474,740 new ordinary shares on 12 April 2024, whereby the number of votes increased with 10,474,740 and the share capital increased with SEK 10,474,740.
May 3, 2024
·
1 min read
Business
Evan Ballantyne to join Hansa Biopharma as Chief Financial Officer
Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA), today announced the appointment of Evan Ballantyne as Chief Financial Officer (CFO), effective 1 March 2024.
February 22, 2024
·
4 min read
Business
Hansa Biopharma Expects Strong First Quarter 2024 Sales Performance
Hansa Biopharma AB expects to report revenue of approximately SEK 54m for Q1 ending March 31, 2024, consisting of SEK 48m in product sales and SEK 6m in revenue recognition primarily related to its agreement with Sarepta Therapeutics, Inc.
April 2, 2024
·
3 min read
Hansa Biopharma Year-end report January-December 2023
Hansa Biopharma, the pioneer in immunomodulatory enzyme technology for rare IgG mediated diseases, announced its business update and year-end report for January to December 2023.
February 2, 2024
·
11 min read
Business
Hansa Biopharma plans restructuring to strengthen long-term competitiveness and advance key deliverables
Hansa Biopharma, “Hansa”, announced that it plans to restructure the organisation to better align and focus on key clinical development and commercial priorities.
December 5, 2023
·
2 min read
Press Releases
Hansa Biopharma to host Q2 2024 interim results conference call
July 3, 2024
·
2 min read
1 of 37,304
Next
